移植片対宿主病(GVHD)治療薬市場:パイプラインレビュー(2020年上半期)

◆英語タイトル:Graft Versus Host Disease (GVHD) - Pipeline Review, H1 2020
◆商品コード:GDATA20MY0944
◆発行会社(リサーチ会社):Global Markets Direct
◆発行日:2020年3月31日
◆ページ数:725
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆調査対象地域:グローバル
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD2,000 ⇒換算¥210,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD4,000 ⇒換算¥420,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD6,000 ⇒換算¥630,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobal Markets Direct社の日本における正規販売代理店です。同社発行の医療分野調査レポートに関するお問い合わせは弊社までお願い致します。
Global Markets Direct社の概要はこちらでご確認いただけます。
※上記「見積依頼/購入/質問フォーム」をクリックすると弊社運営のレポート販売サイトに移動します。

【レポートの概要】

Graft Versus Host Disease (GVHD) – Pipeline Review, H1 2020
Summary

Global Markets Direct’s latest Pharmaceutical and Healthcare disease pipeline guide Graft Versus Host Disease – Pipeline Review, H1 2020, provides an overview of the Graft Versus Host Disease (Immunology) pipeline landscape.

Graft-versus-host disease (GVHD) is a complication that can occur after a stem cell or bone marrow transplant in which the newly transplanted donor cells attack the transplant recipient’s body. Symptoms include abdominal pain or cramps, nausea, vomiting, and diarrhea, dry or irritated eyes, jaundice, shortness of breath, vaginal dryness and weight loss. Treatment includes immunosuppressants.

Report Highlights

Global Markets Direct’s Pharmaceutical and Healthcare latest pipeline guide Graft Versus Host Disease – Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Graft Versus Host Disease (Immunology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Graft Versus Host Disease (Immunology) pipeline guide also reviews of key players involved in therapeutic development for Graft Versus Host Disease (GVHD) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Filing rejected/Withdrawn, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 2, 2, 11, 39, 11, 3, 43, 5 and 3 respectively. Similarly, the Universities portfolio in Phase III, Phase I, Preclinical and Discovery stages comprises 1, 3, 12 and 1 molecules, respectively.

Graft Versus Host Disease (Immunology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Graft Versus Host Disease (Immunology).
- The pipeline guide reviews pipeline therapeutics for Graft Versus Host Disease (Immunology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Graft Versus Host Disease (Immunology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Graft Versus Host Disease (Immunology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Graft Versus Host Disease (Immunology)

Reasons to Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Graft Versus Host Disease (Immunology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Graft Versus Host Disease (Immunology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

【レポートの目次】

Table of Contents
Introduction
Graft Versus Host Disease (GVHD) – Overview
Graft Versus Host Disease (GVHD) – Therapeutics Development
Graft Versus Host Disease (GVHD) – Therapeutics Assessment
Graft Versus Host Disease (GVHD) – Companies Involved in Therapeutics Development
Graft Versus Host Disease (GVHD) – Drug Profiles
Graft Versus Host Disease (GVHD) – Dormant Projects
Graft Versus Host Disease (GVHD) – Discontinued Products
Graft Versus Host Disease (GVHD) – Product Development Milestones
Appendix

List of Tables
Number of Products under Development for Graft Versus Host Disease (GVHD), H1 2020
Number of Products under Development by Companies, H1 2020
Number of Products under Development by Universities/Institutes, H1 2020
Products under Development by Companies, H1 2020
Products under Development by Universities/Institutes, H1 2020
Number of Products by Stage and Target, H1 2020
Number of Products by Stage and Mechanism of Action, H1 2020
Number of Products by Stage and Route of Administration, H1 2020
Number of Products by Stage and Molecule Type, H1 2020
Graft Versus Host Disease (GVHD) - Pipeline by AbbVie Inc, H1 2020
Graft Versus Host Disease (GVHD) - Pipeline by AbGenomics International Inc, H1 2020
Graft Versus Host Disease (GVHD) - Pipeline by Adienne Pharma & Biotech, H1 2020
Graft Versus Host Disease (GVHD) - Pipeline by Alpine Immune Sciences Inc, H1 2020
Graft Versus Host Disease (GVHD) - Pipeline by Amgen Inc, H1 2020
Graft Versus Host Disease (GVHD) - Pipeline by AnaptysBio Inc, H1 2020
Graft Versus Host Disease (GVHD) - Pipeline by apceth Biopharma GmbH, H1 2020
Graft Versus Host Disease (GVHD) - Pipeline by ASC Therapeutics Inc, H1 2020
Graft Versus Host Disease (GVHD) - Pipeline by AstraZeneca Plc, H1 2020
Graft Versus Host Disease (GVHD) - Pipeline by Athersys Inc, H1 2020
Graft Versus Host Disease (GVHD) - Dormant Projects, H1 2020
Graft Versus Host Disease (GVHD) - Discontinued Products, H1 2020

【掲載企業】

AbbVie Inc
AbGenomics International Inc
Adienne Pharma & Biotech
Alpine Immune Sciences Inc
Amgen Inc
AnaptysBio Inc
apceth Biopharma GmbH
ASC Therapeutics Inc
AstraZeneca Plc
Athersys Inc
Autolus Therapeutics Plc
Bellicum Pharmaceuticals Inc
Biocon Ltd
Biogen Inc
BioIncept LLC
BlueRock Therapeutics
Boryung ViGenCell Inc
Bristol-Myers Squibb Co
Capricor Therapeutics Inc
Cellect Biotechnology Ltd
Cellective BioTherapy Inc
Cellix Bio Pvt Ltd
CheckPoint Immunology Inc
Clinigen Group Plc
CSL Ltd
CTI BioPharma Corp
Cytodyn Inc
Cytopeutics Pte Ltd
Daewoong Pharmaceutical Co Ltd
Dualogics Corp
Eli Lilly and Co
Elsalys Biotech SA
enGene Inc
Enlivex Therapeutics Ltd
ExCellThera Inc
F. Hoffmann-La Roche Ltd
Fate Therapeutics Inc
Fujifilm Holdings Corp
Generon (Shanghai) Corp Ltd
GigaGen Inc
GlaxoSmithKline Plc
Glia LLC
Humanigen Inc
Immplacate
Immune Modulation Inc
ImmuneTarget Inc
Imstem Biotechnology Inc
Incyte Corp
Inspyr Therapeutics Inc
Jazz Pharmaceuticals Plc
JN Biosciences LLC
Kadmon Corp LLC
Kalytera Therapeutics Inc
Kamada Ltd
Kiadis Pharma NV
Kiniksa Pharmaceuticals Ltd
Kymab Ltd
LG Chem Ltd
MaaT Pharma
Machavert Pharmaceuticals LLC
Magenta Therapeutics Inc
Mallinckrodt Plc
Medac Pharma Inc
Medicenna Therapeutics Corp
Medsenic SAS
Mereo Biopharma Group Plc
Mesoblast Ltd
Millennium Pharmaceuticals Inc
NapaJen Pharma Inc
Neovii Pharmaceuticals AG
Novartis AG
Ocugen Inc
OncoImmune Inc
OSE Immunotherapeutics
Panorama Research Inc
Pfizer Inc
Pharmicell Co Ltd
Pluristem Therapeutics Inc
Precision Biosciences Inc
REGiMMUNE Corp
Sanofi
SCM lifescience Co Ltd
Seattle Genetics Inc
Secura Bio Inc
STERO Biotechs Ltd
Suzhou Connect Biopharmaceuticals Ltd
Syndax Pharmaceuticals Inc
Synthetic Biologics Inc
Taiwan Bio Therapeutics Co Ltd
Takeda Pharmaceutical Co Ltd
Targazyme Inc
TCF GmbH
TeraImmune Inc
TGV Laboratories Inc
United BioPharma Inc
Vault Pharma Inc
VBI Vaccines Inc
Visterra Inc
Xenikos BV
Xenothera SAS
XL-protein GmbH

【免責事項】
https://www.marketreport.jp/reports-disclaimer

★医療情報レポート[移植片対宿主病(GVHD)治療薬市場:パイプラインレビュー(2020年上半期)]についてメールでお問い合わせはこちら



◆H&Iグローバルリサーチ株式会社のお客様(例)◆